Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms

Katrine Bjune*, Lene Wierød, Soheil Naderi

Unit for Cardiac and Cardiovascular Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway

* kabjun@ous-hf.no

Abstract

Protein kinase B (AKT) is a serine/threonine kinase that functions as an important downstream effector of phosphoinositide 3-kinase. We have recently shown that MK-2206 and triciribine, two highly selective AKT inhibitors increase the level of low density lipoprotein receptor (LDLR) mRNA which leads to increased amount of cell-surface LDLRs. However, whereas MK-2206 induces transcription of the LDLR gene, triciribine stabilizes LDLR mRNA, raising the possibility that the two inhibitors may actually affect other kinases than AKT. In this study, we aimed to ascertain the role of AKT in regulation of LDLR mRNA expression by examining the effect of five additional AKT inhibitors on LDLR mRNA levels. Here we show that in cultured HepG2 cells, AKT inhibitors ARQ-092, AKT inhibitor VIII, perifosine, AT7867 and CCT128930 increase LDLR mRNA levels by inducing the activity of LDLR promoter. CCT128930 also increased the stability of LDLR mRNA. To study the role of AKT isoforms on LDLR mRNA levels, we examined the effect of siRNA-mediated knockdown of AKT1 or AKT2 on LDLR promoter activity and LDLR mRNA stability. Whereas knockdown of either AKT1 or AKT2 led to upregulation of LDLR promoter activity, only knockdown of AKT2 had a stabilizing effect on LDLR mRNA. Taken together, these results provide strong evidence for involvement of AKT in regulation of LDLR mRNA expression, and point towards the AKT isoform specificity for upregulation of LDLR mRNA expression.

Introduction

Low density lipoprotein (LDL) is the major cholesterol-carrying lipoprotein in humans, making up approximately 70% of circulating cholesterol [1]. The maintenance of plasma LDL-cholesterol is primarily carried out by LDL receptor (LDLR) that mediates the endocytotic clearance of LDL from plasma [1]. Thus, mutations in genes that cause a reduction in LDLR levels or function lead to elevated plasma LDL-cholesterol levels which are associated with an increased risk of cardiovascular disease [1, 2]. Consistent with the essential role of the LDLR in regulation of plasma LDL-cholesterol levels, therapies aimed at increasing LDLR levels, such
as statins or antibodies against proprotein convertase subtilisin/kexin type 9, have proven to be the most effective treatments to reduce the incidence of cardiovascular disease [3].

Expression of LDLR is tightly regulated at multiple levels to ensure normal cellular function. At the transcriptional level, the expression of LDLR gene is mainly regulated by sterol regulatory element-binding protein-2 (SREBP-2) [4]. SREBP-2 is a transcription factor that is synthesized as an inactive endoplasmic reticulum (ER) membrane-bound precursor. Upon reduction of intracellular cholesterol levels, SREBP-2 is escorted by SREBP cleavage-activating protein (SCAP) to the Golgi apparatus where SREBP-2 undergoes two sequential proteolytic cleavages to release the transactivation-competent NH2-terminal domain [5, 6]. Once inside the nucleus, the active SREBP-2 binds to its cognate sterol regulatory element-1 (SRE-1) in the LDLR promoter and induces LDLR expression [7, 8]. However, the amount of LDLR mRNA is also regulated by factors that affect the stability of LDLR mRNA. LDLR mRNA is relatively labile, with a half-life of approximately 2 hours [9], and the stability of LDLR mRNA is dictated by regulatory sequences in the 3’untranslated region (3’UTR) that serve as binding sites for mRNA stabilizing and destabilizing trans-regulatory proteins [10, 11].

Even though cholesterol and oxysterol derivatives are the key regulators of SREBP-2, recent studies have shown that SREBP-2 is affected by multiple signaling pathways. One of these pathways is the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway [12]. AKT is a serine/threonine kinase that functions as an important downstream effector of PI3K [12]. In this capacity, AKT integrates and relays signals from a diverse set of extracellular cues to regulate cellular processes such as metabolism, proliferation, growth and survival. Mammalian cells express three structurally homologous AKT isoforms (AKT1, AKT2 and AKT3) that contain an N-terminal pleckstrin homology (PH) domain followed by a central catalytic domain and a C-terminal regulatory domain [13, 14]. The initiating event for activation of AKT is the receptor-stimulated generation of phosphatidylinositol (3,4,5)-triphosphate (PIP3) by PI3K. PIP3 then interacts with the PH domain of AKT and docks it to the plasma membrane where it is activated as a result of phosphorylation on Thr308 in the activation loop and also on Ser473 in the C-terminal regulatory domain by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and mammalian target of rapamycin complex 2 (mTORC2), respectively [15].

We have recently shown that two pharmacologic inhibitors of AKT, MK-2206 and triciribine, increase the levels of LDLR mRNA, leading to increased levels of cell-surface LDLRs [16, 17]. Interestingly, we found that MK-2206 and triciribine utilize two different regulatory mechanisms to trigger the accumulation of LDLR mRNA. Whereas MK-2206 stimulates LDLR gene expression by inducing the proteolytic activation of SREBP-2, triciribine increases the stability of LDLR mRNA. This lack of congruence between the two inhibitors that target the same kinase raised the possibility that the divergent effects of MK-2206 and triciribine on LDLR expression might arise from the result of their interaction with targets other than AKT. If this were the case, then it would be highly unlikely that inhibition of AKT by other means would affect the expression of LDLR. We addressed this notion by examining the effect of a number of functionally different AKT inhibitors or siRNA-mediated AKT knockdown on LDLR expression.

Materials and methods

Reagents and antibodies

MK-2206 2HCl, triciribine, AT7867, ARQ-092 and CCT1298930 were obtained from Selleckchem (Houston, TX). AKT inhibitor VIII and perifosine were from AdooQ Bioscience (Irvine, CA). The kinase inhibitors were dissolved in dimethyl sulfoxide (DMSO; Sigma Aldrich,
St. Louis, MO), except from perifosine which was dissolved in ethanol. Actinomycin D (ActD) and dithiothreitol (DTT) were from Sigma-Aldrich. Antibodies against LDLR (3839-100) and β-tubulin (T9154-05G) were purchased from BioVision (Milpitas, CA) and Nordic BioSite AB (Täby, Sweden), respectively. Antibodies against AKT1 (2938) and AKT2 (2964) were obtained from Cell Signaling (Danvers, MA). siRNAs against AKT1 (Hs_AKT1_7 FlexiTube siRNA) and AKT2 (Hs_AKT2_5 FlexiTube siRNA) were obtained from Qiagen (Hilden, Germany).

**Cell cultures**

HepG2 cells (European Collection of Cell Cultures, Salisbury, UK), were cultured on collagen-coated culture vessels (BD Biosciences, San Jose, CA) in HyClone Minimum Essential Medium (GE Healthcare Life Sciences, Pittsburg, PA) containing 10% fetal bovine serum (Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 50 U/ml penicillin (GE Healthcare Life Sciences), 50 μg/ml streptomycin (GE Healthcare Life Sciences) and non-essential amino acids (BioWest, Nuaille, France). The cells were grown in monolayer in an atmosphere of 5% CO2 at 37˚C. CHO T-REx cells (Invitrogen, Carlsbad, CA) were cultured as previously described [18]. All drugs, except perifosine, were added in DMSO with a constant DMSO concentration of 0.1% (v/v). To control for possible DMSO effects, control samples were treated with DMSO alone at final concentrations of 0.1%.

**Western blot analysis**

Cells were lysed in Triton X-100 lysis buffer (20 mM Tris [pH 7.5], 100 mM NaCl, 1% Triton X-100, 10 mM EDTA and Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland). Equal amounts of proteins were separated by 4-20% sodium dodecyl sulfate polyacrylamide gel electrophoresis. After transfer to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA), proteins were detected by use of standard immunoblotting procedures. The band intensities were quantified by the use of Chemidoc Touch Imaging System (Bio-Rad).

**Quantitative real-time PCR**

Total RNA was extracted from cells using QIAamp RNA Isolation Kit (Qiagen). cDNA was synthesized with the AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies, Santa Clara, CA). Quantitative real-time PCR (qPCR) was performed using Brilliant III Ultra-Fast QPCR Master Mix (Agilent Technologies) on Mx3005P QPCR system (Agilent Technologies). The assay ids of the PrimeTime Predesigned qPCR Assays used (Integrated DNA Technologies, Coralville, IA) are shown in Table 1. The experiments were carried out in duplicate. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalizing the amount of target mRNA. Relative mRNA expression was calculated using the $2^{-\Delta\Delta CT}$ method [19].

| Gene symbol | Assay ID       | Ref. seq                  | Exon location | Assay configuration |
|-------------|----------------|---------------------------|---------------|--------------------|
| AKT1        | Hs.PT.58.26215470 | NM_001014431(3)          | 4-5           | Std, FAM/ZEN/IBFQ, P.P 2 |
| AKT2        | Hs.PT.56a.3591556.g | NM_001243027(3)          | 6-8           | Std, FAM/ZEN/IBFQ, P.P 2 |
| LDLR        | Hs.PT.58.14599757 | NM_000527(6)             | 8-9           | Std, FAM/ZEN/IBFQ, P.P 2 |
| GAPDH       | Hs.PT.39a.22214836 | NM_002046(1)             | 2-3           | Std, FAM/ZEN/IBFQ, P.P 2 |

https://doi.org/10.1371/journal.pone.0218537.t001
Plasmids, transfection and reporter assay

The luciferase reporter plasmid containing the LDLR promoter sequence +58 to -1563, pLR1563-luc [20], was a gift from Dr. Youngmi Kim Pak (University of Ulsan College of Medicine, Seoul, Republic of Korea). For plasmid transfections, cultured HepG2 cells were transfected with 312 ng plasmid DNA/cm$^2$ using FuGENE HD (Promega, Madison, WI) according to the manufacturer’s instructions. A ratio between FuGENE HD and plasmid DNA of 4.5:1 was used. Cells transfected with empty vector were used as a control. AKT inhibitors were added to the cells 24 h after transfection and harvested after 14 h post-addition. Analysis of reporter gene activities was performed by the use of Dual-Luciferase Reporter Assay (Promega), according to the manufacturer’s instructions. For gene knockdown studies, HepG2 cells were transfected with 40 pmol gene-specific or non-targeting (NT) AllStars negative siRNA (Qiagen) using Lipofectamine RNAiMAX (Thermo Fisher Scientific) with cells at 70% confluency. For dual transfection studies with both siRNA and the pLR1563-luc plasmid, cultured HepG2 cells were transfected with 40 pmol siRNA and 312 ng plasmid DNA/cm$^2$ with DharmaFECT Duo Transfection reagent (GE Healthcare Life Sciences) at a ratio of 4:1, according to the manufacturer’s instructions. For measurement of LDLR promoter activity, cells were co-transfected with pLR1563-luc and the Renilla luciferase plasmid, phRL (Promega) at a ratio of 9:1. Cells transfected with empty vector and NT AllStars negative siRNA were used as a control.

RT-PCR analysis of XBPI mRNA splicing to identify ER stress

Total RNA was isolated from CHO T-REx cells using QIAamp RNA Blood Mini Kit (Qiagen). One microgram of RNA was reverse-transcribed using Qiagen Onestep RT-PCR kit (Qiagen) and X-Box Binding Protein 1 (XBPI) cDNA was synthesized using the 5’ primer: 5’-CACCTGAGCCCCGAGGAG-3’ and the 3’ primer: 5’-TTAGTTCATTAAATGGCTTCCAGC-3’. The reverse transcription reaction was run at 50˚C for 30 min. PCR cycling conditions included a 15 min polymerase activation step at 95˚C, followed by 40 cycles of 1 min denaturation at 94˚C, 1 min annealing at 60˚C and 1 min extension at 72˚C. PCR products were subjected to electrophoresis on a 2% agarose gel at 50 V for 240 min and stained with GelRed Nucleic Acid Gel Stain (Biotium, Inc., Fremont, CA).

Statistical analyses

All data are expressed as mean ± SD, except data obtained by qPCR which is expressed as mean ± confidential interval. To determine statistical significance an F-test were first conducted to study whether the treated samples had a variance equal to or different from the control. A two-tailed unpaired Student’s t-test was then used for determination of statistical significance. A p-value < 0.05 was considered statistically significant. The LDLR mRNA half-life was calculated using least squares regression.

Results

AKT inhibitors induce the expression of LDLR

As a first step towards ascertaining whether inhibition of AKT is responsible for induction of LDLR by MK-2206 or triciribine, we examined the effect of additional AKT inhibitors on the LDLR levels. To this end, we set out to examine the expression of LDLR protein levels in HepG2 cells that were exposed to ARQ-092, AKT inhibitor VIII, perifosine, AT7867 or CCT128930 for 14 h. Similar to MK-2206, ARQ-092 and AKT inhibitor VIII are allosteric AKT inhibitors that lock the kinase in a closed, enzymatically inactive conformation [21, 22].
Perifosine is an alkylphospholipid that, similar to triciribine, interferes with the binding of the AKT PH domain to PIP3, consequently inhibiting the kinase activation [23, 24]. AT7867 and CCT138930 are ATP-competitive inhibitors that target and inhibit the phosphorylated conformation of AKT [25, 26]. Except for CCT128930 which exhibits AKT2 isoform selectivity [26], all the above-mentioned inhibitors, including MK-2206 and triciribine, are considered as pan-AKT inhibitors. First, we used phosphorylation of AKT as a readout for its activity to experimentally validate the range of inhibitor concentrations that are reported to inhibit AKT activity [22, 26–30]. Then we treated HepG2 cells with the lowest inhibitor concentration required to markedly inhibit AKT activity, as well as two higher concentrations, and examined the expression of LDLR by Western blot analysis. Fig 1 shows that, similar to MK-2206 and triciribine, all five AKT inhibitors induced the expression of LDLR protein levels in a dose-responsive manner. Importantly, treatment of cells with the GSK3β-selective inhibitor, SB216763, did not increase LDLR levels. These data strongly implicate that inhibition of AKT results in induction of LDLR expression.

**AKT inhibitors increase LDLR mRNA levels**

The MK-2206- and triciribine-mediated accumulation of LDLR occurs as a result of an increase in the LDLR mRNA levels. Therefore, we felt it important to examine whether the induction of LDLR by the other AKT inhibitors was associated with an increase in LDLR mRNA levels. Quantification of LDLR mRNA in HepG2 cells which were treated with AKT inhibitors revealed that, similar to MK-2206 and triciribine, all five inhibitors increased LDLR mRNA levels (Fig 2A).

We then proceeded to investigate the mechanism by which the AKT inhibitors increased LDLR mRNA levels. To examine the effect of these inhibitors on LDLR gene transcription, we cultured HepG2 cells that were transfected with the pLR1563-luc plasmid, a luciferase reporter construct driven by the LDLR promoter, in the absence or presence of the AKT inhibitors for 14 h and then examined them for luciferase activity. As expected, luciferase activity was induced in cells that were treated with MK-2206, whereas triciribine had no effect on luciferase activity (Fig 2B) [16, 17]. Interestingly, all the other AKT inhibitors also exerted a positive effect on luciferase activity. These results indicate that, similar to MK-2206, ARQ-092, AKT inhibitor VIII, perifosine, AT7867 and CCT128930 induce transcriptional activity of the LDLR gene.

To determine the effect of the AKT inhibitors on LDLR mRNA stability, we used the transcriptional inhibitor Act D to examine the effect of the AKT inhibitors on LDLR mRNA degradation. Calculation of LDLR mRNA half-lives showed that, in accordance with our previous findings, triciribine exerted a potent stabilizing effect on LDLR mRNA, whereas MK-2206 minimally inhibited the degradation of LDLR mRNA (Fig 3A and 3B). Whereas LDLR mRNA exhibited a half-life of approximately 2 h in cells that were treated with MK-2206, ARQ-092, AT7867, AKT Inhibitor VII or perifosine, it was significantly stabilized in cells that were exposed to CCT128930 or triciribine, with half-life of 3 h or 5 h, respectively (Fig 3A–3H). Together, these data indicate that ARQ-092, AT7867, perifosine, AKT inhibitor VIII and CCT128930 increased the transcription of LDLR gene in a fashion similar to that of MK-2206. However, similar to triciribine, CCT128930 additionally exerts a stabilizing effect on LDLR mRNA.

**Induction of LDLR gene transcription by AKT inhibitors is not secondary to ER stress**

Transcription of the LDLR gene is dependent on SREBP-2, a transcription factor whose proteolytic activation is sensitive not only to intracellular cholesterol levels but also to ER stress.
Fig 1. AKT inhibitors increase LDLR levels in a dose-responsive manner. HepG2 cells were cultured in the presence of vehicle, the indicated concentrations of AKT inhibitors or the GSK3β inhibitor, SB216763, for 14 h before harvesting for analysis by immunoblotting with antibodies against LDLR and β-tubulin. The figure shows one representative blot from four independent experiments. The bar graphs show quantification of the immunoblots which were scanned and the intensity of the LDLR band was normalized to that of β-tubulin, and plotted relative to the values obtained for vehicle-treated cells, which were set at 1. Error bars represent SD. *p < 0.5 relative to vehicle-treated cells.

https://doi.org/10.1371/journal.pone.0218537.g001
Therefore, given the observation that the majority of the AKT inhibitors used in this study stimulated the \text{LDLR} promoter activity (Fig 2B), we felt it important to ascertain whether the AKT inhibitors induced ER stress. To this end, we treated CHO cells with the AKT inhibitors for 14 h and examined the splicing of \textit{XBP1} mRNA. In response to ER stress, endonuclease inositol-requiring enzyme 1-mediated unconventional splicing of \textit{XBP1} mRNA (\textit{XBP1u}) leads to generation of the shorter, spliced \textit{XBP1} mRNA (\textit{XBP1s}) [33]. As shown in Fig 4, whereas DTT, a disulfide bond reducer and an inducer of ER stress, generates \textit{XBP1s}, none of the AKT inhibitors examined induced the expression of \textit{XBP1s}. This result indicates that induction of \textit{LDLR} mRNA levels by the AKT inhibitors does not occur as a consequence of ER stress.

\textbf{AKT knockdown increases \textit{LDLR} mRNA and \textit{LDLR} protein levels}

All the AKT inhibitors included in this study increased the expression \textit{LDLR}. However, kinase inhibitors are known to have pleiotropic effects [34]. Thus, these inhibitors could in theory mediate their effects on LDLR by mechanisms that do not involve AKT. Therefore, we decided to study the role of AKT inhibition on \textit{LDLR} mRNA levels using siRNA-mediated gene silencing as siRNAs have been shown to exhibit high target specificity [35]. Of the three AKT isoforms, AKT1 is ubiquitously expressed, while AKT2 is primarily expressed in insulin-
Because AKT3 is mainly expressed in testes and the brain and is nearly undetectable in liver-derived cells [36], we focused on the other two AKT isoforms. For these studies, HepG2 cells were transfected with siRNAs against AKT1 or AKT2. Transfected cells were cultured for 40 h and the level of LDLR mRNA was determined by qPCR. As can be seen from Fig 5A, AKT1 and AKT2 mRNA levels were reduced by 81% and 90%, respectively, in siRNA-treated cells. Importantly, knockdown of AKT1 or AKT2 led to induction of LDLR mRNA levels by 23% and 50%, respectively (Fig 5A).

![Fig 3. Effect of AKT inhibitors on the stability of LDLR mRNA.](https://doi.org/10.1371/journal.pone.0218537.g003)
To examine whether knockdown of AKT1 or AKT2 also increased LDLR protein levels, HepG2 cells were transfected with siRNAs against AKT1 or AKT2 and LDLR protein levels was determined by Western blot analysis. As can be seen from Fig 5B, knockdown of AKT1 or AKT2 increased the LDLR protein level, suggesting that the effect of the AKT inhibitors on LDLR is mediated by their inhibitory effect on AKT.

AKT1 and AK2 affect LDLR mRNA levels by different mechanisms

Assuming that the kinase inhibitors used in this study exhibit AKT isoform preference in vivo, the dichotomy between the mechanisms that are utilized by different AKT inhibitors to induce the expression of LDLR would suggest that AKT regulates the LDLR expression machinery in an isoform-specific manner. To assess the plausibility of this notion, we decided to examine the effect of AKT isoform-specific knockdown on LDLR promoter activity and LDLR mRNA stability. First, we examined the luciferase activity in HepG2 cells that were co-transfected with the LDLR promoter reporter plasmid pLR1563-luc and either AKT1-specific siRNA or AKT2-specific siRNA. As shown in Fig 6A, treatment of cells with either AKT1 siRNA or AKT2 siRNA led to induction of luciferase activity by 70% and 47%, respectively. To examine whether AKT-specific knockdown affects LDLR mRNA stability, we cultured HepG2 cells that were transfected with AKT1 or AKT2 siRNAs in the absence or presence of Act D for 6 h and then examined LDLR mRNA levels by qPCR. As shown in Fig 6B, only AKT2 knockdown resulted in increased LDLR mRNA stability. Taken together, these results suggest that while both AKT1 and AKT2 are involved in regulation of LDLR expression, only AKT2 plays a role in modulation of LDLR mRNA stability.

Discussion

We have recently shown that inhibition of AKT by two small molecular inhibitors, MK-2206 and triciribine, increases the level of LDLR mRNA [16, 17]. Mechanistically, we showed that MK-2206 induces the proteolytic cleavage of SREBP-2 and thus stimulates LDLR gene transcription. In contrast, triciribine induces LDLR mRNA levels by decreasing its turnover rate. Given the potential for off-target effects often associated with pharmacological inhibition agents, we considered it necessary to verify or falsify whether this apparent discrepancy between the effects of MK-2206 and triciribine on the LDLR expression machinery occurs as the result of inhibition of kinases other than AKT. To this end, we argued that structurally and
functionally different kinase inhibitors that share the same target are highly unlikely to produce the same off-target effect and initiated the current study to examine the effect of five additional AKT inhibitors on LDLR expression. This panel of AKT inhibitors consisted of two allosteric inhibitors, ARQ-092 and AKT inhibitor VIII, one PH domain-interacting inhibitor, perifosine, and two ATP-competitive inhibitors, AT78806 and CCT128930. As expected, all AKT inhibitors inhibited AKT and its downstream substrates PRAS40 and GSK3β, but had no effect on ERK-phosphorylation (S1 Fig). We found that, similar to MK-2206, all inhibitors used in this study exhibited an inducing effect on LDLR promoter activity, albeit with varying degree. In contrast, only the ATP-competitive and AKT2-specific inhibitor, CCT128930, behaved as triciribine and increased the stability of LDLR mRNA. These results strongly suggested that inhibition of AKT is responsible for upregulation of LDLR expression but did not shed light on the mechanism that dictates the mode of AKT inhibition-mediated induction of
LDLR. Initially, we hypothesized that the inhibitor-bound conformation of AKT might determine whether LDLR expression is induced by stimulation of its promoter activity or inhibition of its mRNA degradation. If this were the case, then inhibitors that induce similar conformational changes in AKT would be expected to induce LDLR expression by the same mechanism. However, the lack of congruence between the LDLR-inducing mechanisms utilized by inhibitors with similar mode of action (S2 Fig) suggested that this hypothesis is unlikely to be true.

Given the fact that AKT family consists of three isoforms that exhibit distinct, non-redundant functions [37], together with the observation that the AKT2-specific inhibitor, CCT128930, was the only inhibitor that, increased LDLR mRNA stability, led us to consider the possibility that AKT isoforms might differentially regulate LDLR expression. Indeed, the result obtained using AKT isoform-specific siRNAs lend support to this hypothesis and suggest that while inhibition of AKT1 increases LDLR promoter activity, abrogation of AKT2 induces not only LDLR gene expression but also the stability of its mRNA. In support of this conclusion, we would like to note that the notion that different inhibitors of the same kinase use different mechanisms to achieve the same phenotype is not without precedence. For instance, a meta-analysis of the effect of various inhibitors of the epidermal growth factor receptor has shown that whereas Gefitinib inhibits cellular proliferation by inducing the expression of cell cycle inhibitors, Erlotinib does so by suppressing the expression of cell cycle promoters [38].

Our data showing that inhibition of AKT increases LDLR levels suggest that inhibitors of AKT may have potential as lipid-lowering drugs. However, given the involvement of AKT in a
diverse set of cellular processes, it is reasonable to raise concern that AKT inhibitors might cause unacceptable side-effects that would preclude their use as hypocholesterolemic agents. Indeed, results from several cancer clinical trials concerning the anti-neoplastic effect of AKT inhibitors show that inhibition of AKT is associated with a number of side-effects [39–42]. It is therefore of considerable importance to examine whether the AKT inhibitor doses needed to achieve a sufficient reduction in LDL cholesterol levels would cause adverse effects. Should this prove to be the case, use of AKT isoform-specific inhibitors would allow for reduction of LDL cholesterol levels without inhibition of the AKT isoform whose inhibition is associated with side-effects.

**Supporting information**

S1 Fig. Effect of AKT inhibitors on AKT isoforms, AKT substrates and ERK. (PDF)

S2 Fig. Schematic representation of the mode of action of AKT inhibitors. (PDF)

**Author Contributions**

Conceptualization: Katrine Bjune, Soheil Naderi.

Data curation: Katrine Bjune, Lene Wierød.

Project administration: Soheil Naderi.

Supervision: Soheil Naderi.

Writing – original draft: Katrine Bjune.

Writing – review & editing: Katrine Bjune, Lene Wierød, Soheil Naderi.

**References**

1. Goldstein J, Hobbs H, Brown M. The Metabolic & Molecular Bases of Inherited Disease. McGraw-Hill, New York; 2001.
2. Varret M, Abifadel M, Rabes JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet. 2008; 73(1):1–13. https://doi.org/10.1111/j.1399-0004.2007.00915.x PMID: 18028451
3. Gupta A, Guyomard V, Zaman MJ, RehmanHU, Myint PK. Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Adv Ther. 2010; 27(6):348–364. https://doi.org/10.1007/s12325-010-0033-6 PMID: 20533012
4. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006; 124(1):35–46. https://doi.org/10.1016/j.cell.2005.12.022 PMID: 16413480
5. Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol. 2007; 19(2):215–222. https://doi.org/10.1016/j.ceb.2007.02.004 PMID: 17303406
6. Brown MS, Radhakrishnan A, Goldstein JL. Retrospective on Cholesterol Homeostasis: The Central Role of Scap. Annu Rev Biochem. 2018; 87:783–807. https://doi.org/10.1146/annurev-biochem-062917-011852 PMID: 28841344
7. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest. 1998; 101(11):2331–2339. https://doi.org/10.1172/JCI92961 PMID: 9616204
8. Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci USA. 1993; 90(24):11603–11607. https://doi.org/10.1073/pnas.90.24.11603 PMID: 7903453
9. Pak YK, Kanuck MP, Berrios D, Briggs MR, Cooper AD, Ellsworth JL. Activation of LDL receptor gene expression in HepG2 cells by hepatocyte growth factor. J Lipid Res. 1996; 37(5):985–998. PMID: 8725151

10. Wilson GM, Vasa MZ, Deelley RG. Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 3’ untranslated region. J Lipid Res. 1998; 39(5):1025–1032. PMID: 9610769

11. Yashiro T, Yokoi Y, Shimizu M, Inoue J, Sato R. Chenodeoxycholic acid stabilization of LDL receptor mRNA depends on 3’-untranslated region and AU-rich element-binding protein. Biochem Biophys Res Commun. 2011; 409(2):155–159. https://doi.org/10.1016/j.bbrc.2011.04.006 PMID: 21473855

12. Krycer JR, Sharpe LJ, Luu W, Brown AJ. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab. 2010; 21(5):268–276. https://doi.org/10.1016/j.tem.2010.01.001 PMID: 20117946

13. Barnett SF, Deleo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J. 2005; 385(Pt 2):399–408. https://doi.org/10.1042/BJ20041140 PMID: 15456405

14. Zhou GL, Tucker DF, Bae SS, Bhatheja K, Birbaum MJ, Field J. Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. J Biol Chem. 2006; 281(47):36443–36453. https://doi.org/10.1074/jbc.M600788200 PMID: 17012749

15. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261–1274. https://doi.org/10.1016/j.cell.2007.06.009 PMID: 17604717

16. Bjune K, Sundvold H, Leren TP, Naderi S. MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potent hypocholesterolemic agent. Atherosclerosis. 2018; 276:28–38. https://doi.org/10.1016/j.atherosclerosis.2018.07.009 PMID: 30252552

17. Bjune K, Wierd L, Naderi S. Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA. Sci Rep. 2018; 8(1):16174. https://doi.org/10.1038/s41598-018-34237-6 PMID: 30385871

18. Holla L, Strom TB, Cameron J, Berge KE, Leren TP. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9. Mol Genet Metab. 2010; 99(2):149–156. https://doi.org/10.1016/j.ymgme.2009.09.012 PMID: 19828345

19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609

20. Oh J, Choi YS, Kim JW, Park JY, Kim SW, Park KK, et al. Inhibition of low density lipoprotein receptor expression by long-term exposure to phorbol ester via p38 mitogen-activated protein kinase pathway. J Cell Biochem. 2005; 96(4):786–794. https://doi.org/10.1002/jcb.20551 PMID: 16149074

21. Yan L. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. Cancer Research. 2009; 69(9 Supplement):DDT01-1–DDT01-1.

22. Yu Y, Savage RE, Eathiraj S, Meade J, Wick MJ, Hall T, et al. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS ONE. 2015; 10(10):e0140479. https://doi.org/10.1371/journal.pone.0140479 PMID: 26496992

23. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004; 64(13):4394–4399. https://doi.org/10.1158/0008-5472.CAN-04-0343 PMID: 15231645

24. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012; 8(5):623–633. https://doi.org/10.1517/17425255.2012.681376 PMID: 22512706

25. Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton Ml, Woodhead SJ, et al. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther. 2010; 9(5):1100–1110. https://doi.org/10.1158/1535-7163.MCT-09-0986 PMID: 20423992

26. Yap TA, Walton Ml, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, et al. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther. 2011; 10(2):360–371. https://doi.org/10.1158/1535-7163.MCT-10-0769 PMID: 21191045

27. Zhang S, Deng Z, Yao C, Huang P, Zhang Y, Cao S, et al. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms. PLoS ONE. 2017; 12(1):e0169585. https://doi.org/10.1371/journal.pone.0169585 PMID: 28081222
28. Pinton G, Manente AG, Angeli G, Mutti L, Moro L. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS ONE. 2012; 7(5):e36856. https://doi.org/10.1371/journal.pone.0036856 PMID: 22590625

29. Myers AL, Lin L, Nancarrow DJ, Wang Z, Ferrer-Torres D, Thomas DG, et al. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma. Oncotarget. 2015; 6(28):25897–25916. https://doi.org/10.18632/oncotarget.4532 PMID: 25317790

30. Vivanco I, Chen ZC, Tanos B, OLDrini B, Hsieh WY, Yannuzzi N, et al. A kinase-independent function of AKT promotes cancer cell survival. Elife. 2014; 3. https://doi.org/10.7554/eLife.03751 PMID: 25551293

31. Lee JN, Ye J. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. J Biol Chem. 2004; 279(43):45257–45265. https://doi.org/10.1074/jbc.M408235200 PMID: 15304479

32. Colgan SM, Tang D, Werstuck GH, Austin RC. Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int J Biochem Cell Biol. 2007; 39(10):1843–1851. https://doi.org/10.1016/j.biocel.2007.05.002 PMID: 17604677

33. Yoshida H, Matsu T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001; 107(7):881–891. https://doi.org/10.1016/S0092-8674(01)00611-0 PMID: 11779464

34. Tan S, Ng Y, James DE. Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochem J. 2011; 435(2):539–544. https://doi.org/10.1042/BJ20110040 PMID: 21348862

35. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA. 2003; 100(11):6347–6352. https://doi.org/10.1073/pnas.1131959100 PMID: 12746500

36. Bellacosa A, Testa JR, Moore R, Larue L. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther. 2004; 3(3):268–275. https://doi.org/10.4161/cbt.3.3.703 PMID: 15034304

37. Iacovides DC, Johnson AB, Wang N, Bodapati S, Korkola J, Gray JW. Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Mol Cell Proteomics. 2013; 12(11):3210–3220. https://doi.org/10.1074/mcp.M112.023119 PMID: 23929892

38. Blumenberg M. Differential transcriptional effects of EGFR inhibitors. PLoS ONE. 2014; 9(9):e102466. https://doi.org/10.1371/journal.pone.0102466 PMID: 25184905

39. Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, et al. A phase 1 study evaluating the combination of an allostERIC AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013; 15(6):R110. https://doi.org/10.1186/bcr3577 PMID: 24252402

40. Yap TA, Yan L, Patnaik A, Tunaru N, Biondo A, Fearen I, et al. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res. 2014; 20(22):5672–5685. https://doi.org/10.1158/1078-0432.CCR-14-0688 PMID: 25239610

41. Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, et al. Phase 2 study of MK-2206, an allostERIC inhibitor of AKT, as second-line therapy for advanced gastric and gastro-esophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer. 2015; 121(13):2193–2197. https://doi.org/10.1002/cncr.29363 PMID: 25827820

42. Saura C, Roda D, Rosello S, Oliveira M, Macarulla T, Perez-Fidalgo JA, et al. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discov. 2017; 7(1):102–113. https://doi.org/10.1158/2159-8290.CD-16-0512 PMID: 27872130